Genoskin enters a new growth phase

In September, the Toulouse-based biotech company specialising in skin biology and immunology raised €8 million in Series A funding. The company plans to use the funding to double its size and production capacity, while strengthening its commercial presence in the United States, Europe, and Asia. Genoskin has developed a more ethical and predictive alternative to animal testing and in silico models. Its ex vivo human skin explants, which are derived from donated skin samples, remain viable for aweek and can be used to assess the toxicity and efficacy of cosmetics, pharmaceuticals, and biotechnology products. The data is then analysed using AI and bioinformatics. Investors in the funding round included OCCTE (FPCI Occidev Impacts), CaptechSanté, GSO Innovation and CA Toulouse 31 initiatives (CAT31i). Following this fundraising, Genoskin has welcomed Julien Gomis and Emmanuelle Ostiari (OCCTE), Alexandre Demailly (Captech Santé), and Anaïs Raluy (GSO) to its board of directors.